Search Results

Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc.

Graybug Vision, Inc. announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

Graybug Vision, Inc. announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, reported financial results for the three and nine months ended September 30, 2022.

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source (OIS) Retina Innovation Summit, to be held in New York City on July 13, 2022.

Graybug Vision, Inc. today announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, to be held in Washington, D.C. from April 22-26, 2022.

Graybug Vision, Inc. announced its participation in three upcoming medical and investor conferences:

Graybug Vision, Inc. today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022.

Graybug Vision, Inc. announced the hiring of six new employees who will enhance Graybug’s Research & Development, Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022.